OBJECTIVE: To investigate the "real world" effectiveness of Traditional Chinese Medicine (TCM) in patients with acute myocardial infarction suffering from diabetes mellitus (AMI+DM patients).
INTRODUCTION
Acute myocardial infarction (AMI) is a common, acute and severe cardiovascular disease that is prone to various types of serious complications and which can increase mortality risk. With extensive application of thrombolysis and interventional therapy, the preva-lence of mortality of AMI has been reduced considerably worldwide. 1 However, the effect of thrombolysis and interventional therapy is poor if AMI patients also suffer from diabetes mellitus (DM). This combination of diseases is not conducive to reperfusion and establishment of a collateral circulation owing to damage to the microcirculation and arteriole narrowing. Such patients are more likely to suffer from heart failure, arrhythmia, shock and other complications. 2 Therefore, improvement of the prognosis of AMI patients suffering from DM (i.e., AMI+DM patients) is a focus of clinical research. Traditional Chinese Medicine (TCM) has been used widely in the treatment and secondary prevention of AMI and DM. TCM can improve the prognosis of AMI and DM, 3, 4 suggesting that TCM could improve the prognosis of AMI + DM patients. The true benefit of TCM on AMI + DM patients has not been shown clearly.
In the present study, we investigated the effect of TCM and the endpoint events of AMI + DM patients. In this way, our study focused on the "real world" effectiveness of TCM for AMI + DM patients.
MATERIALS AND METHODS

Design of our cohort study
The study protocol was approved by the Medical Ethics Committee of the Affiliated Hospital of Shandong University of TCM (Shandong, China). Injections of Chinese herbal extracts ("TCM injections") were the main treatment for AMI + DM patients during hospitalization. The "exposure group" comprised patients who underwent application of a TCM injection ≥ 7 d. The exposure group was subdivided into the "low-exposure group" (who had a TCM injection for 7-13 d) and a "high-exposure group" (who had a TCM injection for ≥ 14 d). During follow-up, TCM treatment for AMI + DM patients was Chinese patent medicines and decoctions of Chinese medicines. During follow-up, the definition of the exposure group was application of Chinese patent medicine or decoction of Chinese medicine for ≥ 28 d. Subdivision of the exposure group led to a low-exposure group (application of Chinese patent medicine or decoction of Chinese medicine for ≥ 28 d and < 3 months), medium-exposure group (≥ 3 months and < 6 months) and high-exposure group (≥ 6 months). It has been reported that the prevalence of endpoint events in AMI patients treated with TCM is 2% , and that the prevalence of endpoint events in AMI patients not treated with TCM is 17% . the estimated sample size was 168 cases. Hence, 263 AMI patients needed to be enrolled in our study if the in-hospital mortality was 20% and loss to follow-up was < 20%.
Patients
According to the diagnostic criteria of MI and DM, 7, 8 
Outcome
Identification numbers of patients were retrieved through the medical record information management system (MRIMS) of the particular TCM hospital. Patients who met the included criteria were enrolled. General information such as age, sex, contact details, complications, TCM use, and endpoint events (e.g., cardiac death, cardiac shock, acute heart failure, re-infarction, stroke) were collected through the MRIMS from 1 July 2014 to 30 June 2015. The TCM use and endpoint events of AMI + DM patients discharged from a particular TCM hospital were followed up through telephone conversations and outpatient clinics from 1 July 2015 to 31 September 2015. There were three potential biases in the present study: patient recruitment was not comprehensive; the information collected was inaccurate; there was recall bias at follow-up. To reduce the effect of such biases, a series of measures were adopted: patients who met the inclusion criteria were retrieved through the MRIMS; a double-entry test was used to ensure the accuracy of the data; researchers were trained to ensure that follow-up results were reliable.
Data management and statistical methods
EpiData v3.02 (Copenhagen, Denmark) was used to establish a database of AMI + DM patients. Data were entered into this database and exported to Excel™ 2003 (Microsoft, Redmond, MA, USA). According to application of a TCM injection, Chinese patent medicine and decoction of Chinese medicine, the exposure intensity of patients was classified. The prevalence of endpoint events in each exposure group and non-exposure group was calculated. SPSS v18.0 (IBM, Armonk, NY, USA) was used for all analyses. Measurement data are the mean ± standard deviation and were assessed using the Student's t-test. Enumeration data were evaluated with the χ 2 test. Multiple logistic regression was used to analyze the correlation between endpoint events and TCM use. P < 0.05 was considered significant.
RESULTS
General information and follow-up
A total of 479 cases aged (67 ± 10) years hospitalized for (19 ± 11) d formed the study cohort (Table 1 ) and 345 cases were followed up. The duration of follow-up was 6-81 (mean, 32 ± 16) months. Seventy-two cases could not be contacted, so 17.27% of patients were lost to follow-up.
TCM treatment
According to the definition of "exposure", 168 cases were in the high-exposure group, 178 patients in the low-exposure group, and 133 cases in the non-exposure group during hospitalization. During follow-up, 101 cases were in the high-exposure group, 72 patients in the medium-exposure group, 76 cases in the low-exposure group, and 96 cases in the non-exposure group.
Endpoint events
During hospitalization, the most prevalent endpoint event was post-infarction angina (27.77% ), followed by acute heart failure (15.66% ), and cardiac death (12.73%). During follow-up, the most prevalent endpoint event was re-hospitalization due to cardiovascular disease (30.43% ), followed by cardiac death (21.74% ) and post-infarction angina (16.52%). The prevalence of each endpoint event in each group during hospitalization and follow-up is shown in Tables 2 and 3, respectively.
Multiple logistic regression analysis
Related factors were set as independent variables. Multiple logistic regression was used to analyze the relevant factors of the endpoint events of AMI + DM patients during hospitalization and follow-up (Table 4 (Table 5) . During follow-up, TCM (OR = 1.339, 95% CI = 1.060-1.691) was associated with cardiac death. TCM (1.836, 1.375-2.453) was a relevant factor for a composite endpoint of re-infarction and stroke. TCM Table 1 (Table 6 ).
DISCUSSION
DM is considered to be a major risk factor for coronary heart disease (which is a major risk factor for cardiovascular disease). DM patients with coronary heart disease can have a wide range and considerable number of coronary lesions and a poor collateral circulation. The risk of acute coronary syndrome and death is higher in DM patients than in non-DM patients. [8] [9] [10] [11] [12] [13] The ef- Table 6 Multiple logistic correlation analysis of end point events during the follow-up period Notes: B value represents the partial regression coefficient. The OR value represents adjusted odds ratio. Statistically significant at P < 0.05. X1-X9 represent exposure, age, gender, hypertension, dyslipidemia, anti-thrombotic therapy, anti-myocardial ischemia therapy, lipid lowering therapy, angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), respectively.
fect of thrombolysis and interventional therapy is poor in AMI + DM patients owing to coronary lesions being more complex and thrombotic load more severe. AMI + DM patients can suffer from arrhythmia, cardiac shock and congestive heart failure, and the prevalence of recurrence is higher after remission, which can increase the risk of death.
Research has shown that a combination of TCM and Western Medicine may be better than Western Medicine alone for the prevention and treatment of coronary heart disease caused by DM.
14 Anti-coagulation, lipid regulation, as well as protection of vascular endothelial cells and the myocardium may be the advantages of TCM. The latter may have important roles in improvement of the prognosis of AMI + DM patients, but high-quality studies are lacking. The occurrence of AMI within 28 d is, in general, referred to as the "acute phase", and followed by a recovery period. 15 In the present study, TCM and endpoint events during hospitalization and follow-up were investigated separately because of the different pathologic characteristics in the different periods of AMI. The correlation between TCM and endpoint events of AMI + DM patients during hospitalization was analyzed. During hospitalization, TCM, age, hypertension and ACEI/ARB use were associated with cardiac death. Age and dyslipidemia were relevant factors for acute heart failure. Age and hypertension were related to cardiac shock. Hypertension was a relevant factor of the composite endpoint of re-infarction and stroke. Lipid-lowering therapy exhibited a strong correlation with severe arrhythmia. During follow-up, TCM was associated with cardiac death. TCM was a relevant factor for a composite endpoint of re-infarction and stroke. TCM, anti-thrombotic therapy and lipid-lowering therapy were related to acute heart failure. TCM, anti-thrombotic therapy, anti-MI therapy and ACEI/ARB use exhibited a strong correlation with re-hospitalization due to cardiovascular disease. The present study showed a significant correlation of TCM with cardiac death (r = 0.711 , P = 0.000) during hospitalization and cardiac death (r = 0.292, P = 0.014), a composite endpoint of re-infarction and stroke (r = 0.608, P = 0.000), acute heart failure (r = 0.340, P = 0.030), and re-hospitalization due to cardiovascular disease (r = 0.246, P = 0.025) during follow-up. TCM improved the short-term and long-term prognosis of AMI + DM patients significantly (P < 0.05), an observation that is consistent with the work of Naj and colleagues. In their cohort study, 248 AMI patients were followed up. They found that Buchang naoxintong capsules decreased endpoint events such as death, re-infarction, severe heart failure, revascularization and stroke significantly. 16 According to TCM theory, the primary pathologic factors in the early stage of AMI are blood stasis, phlegm blockade, and cold coagulation. The principle of treatment is promotion of blood circulation, phlegm elimination, and warming of heart veins. After pain relief, Qi deficiency and blood stasis are the main problems, so Qi supplementation and activation of the blood circulation are needed. According to TCM theory, the primary pathologic factors of DM are a deficiency of Qi and Yin. The main treatment principles are to supplement Qi and nourish Yin. The main effects of TCM are to supplement Qi, activate the blood circulation and nourish Yin. A series of basic-science studies have shown that TCM can strengthen heart function and improve the blood circulation. 17, 18 TCM can ease symptoms during hospitalization, avoid adverse events after hospital discharge and improve the quality of life of patients. This present study showed that age and dyslipidemia were risk factors for the prognosis of AMI+DM patients, findings that are consistent with those of other studies. 19, 20 Hypertension was a protective factor for cardiac death, cardiac shock, and a composite endpoint of re-infarction and stroke during hospitalization. This observation may have been related to the high perfusion in the peripheral circulation of hypertensive patients, which reduced the prevalence of re-infarction, stroke, cardiac shock and cardiac death. Our study suggested that lipid-lowering therapy and ACEI/ARB use were protective factors for the prognosis of AMI + DM patients during hospitalization, findings that are consistent with other reports. 21, 22 However, anti-thrombotic therapy was a risk factor for acute heart failure in AMI + DM patients during follow-up. This phenomenon may have been related to non-rational use of anti-thrombotic drugs during follow-up. Therefore, future studies should focus on the efficacy of anti-thrombotic drugs in real-world scenarios, and guide the rational use of drugs to improve the prognosis of patients. As with any cohort study, the main limitations of our study were bias and confounding factors. Also, AMI + DM patients admitted to TCM hospitals and enrolled in our study may not have been representative of all AMI + DM patients in China. In addition, although we controlled for potential confounding factors, we could not exclude the effect of other unmeasured factors (the history of smoking and drinking) that may have affected the prognosis of AMI + DM patients.
In conclusion, our study presented evidence suggesting that TCM, age and complications (hypertension, dyslipidemia) were associated with endpoint events in AMI + DM patients. TCM reduced the prevalence of cardiac death during hospitalization and cardiac death, a composite endpoint of re-infarction and stroke, acute heart failure and re-hospitalization due to cardiovascular disease during follow-up.
